Release form, composition and packing
Tablets, enteric-coated cover white or almost white, round, biconvex.
1 tab. acetylsalicylic acid 100 mg.
Excipients: microcrystalline cellulose, lactose, stearic acid, methacrylic acid copolymer (methacrylic acid-etakrilat), propylene glycol, titanium dioxide, talc.
Clinico-pharmacological group: NSAID. Antiaggregant.
Pharmacological action
NSAIDs antiaggregant. The mechanism of action of aspirin is irreversible inhibition of cyclooxygenase-1 (COX-1), as a result of this blockade occurs thromboxane A2 synthesis and suppression of platelet aggregation.
It is believed that aspirin has other mechanisms of suppression of platelet aggregation, which broadens its scope in various vascular diseases. Aspirin is also anti-inflammatory, analgesic, antipyretic action.
Pharmacokinetics
Suction
After oral acetylsalicylic acid absorbed from the upper part of the small intestine. Cmax plasma levels observed after an average of 3 hours after taking the drug inside.
Metabolism
Acetylsalicylic acid undergoes partial metabolism in the liver with formation of less active metabolites.
Breeding
Excreted by the kidneys as unchanged or as metabolites.
T1 / 2 of acetylsalicylic acid is about 15 min for metabolites - about 3 hours
Statement
prevention of acute myocardial infarction in the presence of risk factors (eg, diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, old age);
prevention of recurrent myocardial infarction;
unstable angina;
prevention of stroke (including patients with transient ischemic attack);
prevention of transient ischemic attacks;
prevention of thromboembolism after surgery and invasive procedures on vessels (eg, coronary artery bypass surgery, carotid endarterectomy, arterio-venous bypass, angioplasty of the carotid arteries);
prevention of deep vein thrombosis and pulmonary embolism and its branches (eg, prolonged immobilization as a result of a large surgical intervention).
Dosing regimen
Tablets, taken orally, before eating, drinking plenty of fluids. Prophylaxis for suspected acute myocardial infarction: 100-200 mg / day (the first pill must be chewed for faster absorption). Prevention first mooted acute myocardial infarction in the presence of risk factors: 100 mg / day.
Prevention of recurrent myocardial infarction, unstable angina, prevention of stroke and transient ischemic attacks, prevention of thromboembolic complications after surgery or invasive investigations: 100-300 mg / day.
Prevention of deep vein thrombosis and pulmonary embolism and its branches: 100-200 mg / day. The drug is designed for prolonged use. The duration of therapy is determined by your doctor.
Side effect
From the digestive system: nausea, heartburn, vomiting, pain in the abdomen, ulceration of the mucous membrane of the stomach and duodenum (including perforated), gastrointestinal bleeding, elevated liver enzymes.
With the respiratory system: bronchospasm.
From the hemopoietic system: increased bleeding, rarely - anemia.
CNS: dizziness, ringing in the ears. Allergic reactions: urticaria, angioedema, anaphylactic reaction.
Contraindications
erosive and ulcerative lesions of the gastrointestinal tract;
gastrointestinal bleeding;
hemorrhagic diathesis;
Bronchial asthma induced by intake of salicylates and NSAIDs, Fernand-Widal triad (a combination of asthma, recurrent polyposis of the nose and paranasal sinuses and the intolerance of acetylsalicylic acid);
combined use with methotrexate 15 mg per week or more;
I and III trimesters of pregnancy;
Lactation (breastfeeding);
age 18;
hypersensitivity to the drug;
hypersensitivity to other NSAIDs.
Caution should be used to treat gout, hyperuricemia, guidance on the history of gastrointestinal ulceration or gastrointestinal bleeding, kidney and liver failure, asthma, chronic respiratory disease, hay fever, nasal polyposis, allergic reactions to other drugs in the II trimester pregnancy, in combination with methotrexate at a dose of less than 15 mg per week. with vitamin K deficiency and glucose-6-phosphate dehydrogenase.
Pregnancy and lactation
The use of salicylates in high doses in the I trimester of pregnancy is associated with an increased frequency of fetal defects (split the sky, heart defects). In the II trimester salicylate may be given only on the basis of strict evaluation of the risks and benefits. In the III trimester of pregnancy salicylates in high doses (300 mg / day) cause inhibition of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and the appointment immediately before delivery may cause intracranial hemorrhage, especially in preterm infants. Appointment of salicylates in the III trimester of pregnancy is contraindicated. Salicylates and their metabolites in small amounts are excreted in breast milk.
Incidental taking of salicylates during lactation is not accompanied by the development of adverse reactions in children and does not require stopping breastfeeding. However, if necessary, prolonged use of a drug or appointing him to a high dose of breast-feeding should be stopped immediately.
Use in hepatic dysfunction
Caution should be used when specifying a history of liver failure. Use in renal impairment with caution should be used when specifying a history of renal failure.
Cautions
Aspirin can provoke bronchospasm and cause bronchial asthma and other hypersensitivity reactions. Risk factors are the presence of asthma history, hay fever, nasal polyposis, chronic respiratory system diseases, and allergic reactions to other drugs (eg, skin reactions, pruritus, urticaria).
Aspirin can cause bleeding of varying severity during and after surgery. The combination of aspirin with anticoagulants, thrombolytic and antiplatelet drugs is accompanied by an increased risk of bleeding. Aspirin in low doses can provoke the development of gout in susceptible individuals (who have a decreased excretion of uric acid).
The combination of acetylsalicylic acid with methotrexate is accompanied by a high incidence of side effects of hematopoiesis. High doses of aspirin have a hypoglycemic effect that must be borne in mind when assigning it to patients with diabetes receiving hypoglycemic medications.
When combined appointment of the SCS and salicylates should be borne in mind that during treatment the level of salicylate in the blood is reduced, and after withdrawal of GCS possible overdose of salicylates. Not recommended combination of acetylsalicylic acid and ibuprofen, as the latter affects the beneficial effect Aspikora on life expectancy. Excess doses of aspirin carries a risk of gastrointestinal bleeding.
Overdose is especially dangerous in elderly patients.
In combination with acetylsalicylic acid and alcohol increased the risk of gastrointestinal mucosal lesions and bleeding time prolongation.
Effects on ability to drive vehicles and management mechanisms
There were no effects of the drug's ability to drive vehicles and management mechanisms.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: a reduction in dose. Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory insufficiency, severe hypoglycemia.
Treatment: immediate hospitalization in a specialized department for emergency treatment - gastric lavage, determination of the acid-alkaline balance, alkaline and forced alkaline diuresis, hemodialysis, the introduction of solutions, activated charcoal, symptomatic therapy.
During alkaline diuresis is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be undertaken when the concentration of salicylate in plasma is more than 500 mg / L (3.6 mg / dL) in adults and 300 mg / L (2.2 mg / dL) in children.
Tablets, enteric-coated cover white or almost white, round, biconvex.
1 tab. acetylsalicylic acid 100 mg.
Excipients: microcrystalline cellulose, lactose, stearic acid, methacrylic acid copolymer (methacrylic acid-etakrilat), propylene glycol, titanium dioxide, talc.
Clinico-pharmacological group: NSAID. Antiaggregant.
Pharmacological action
NSAIDs antiaggregant. The mechanism of action of aspirin is irreversible inhibition of cyclooxygenase-1 (COX-1), as a result of this blockade occurs thromboxane A2 synthesis and suppression of platelet aggregation.
It is believed that aspirin has other mechanisms of suppression of platelet aggregation, which broadens its scope in various vascular diseases. Aspirin is also anti-inflammatory, analgesic, antipyretic action.
Pharmacokinetics
Suction
After oral acetylsalicylic acid absorbed from the upper part of the small intestine. Cmax plasma levels observed after an average of 3 hours after taking the drug inside.
Metabolism
Acetylsalicylic acid undergoes partial metabolism in the liver with formation of less active metabolites.
Breeding
Excreted by the kidneys as unchanged or as metabolites.
T1 / 2 of acetylsalicylic acid is about 15 min for metabolites - about 3 hours
Statement
prevention of acute myocardial infarction in the presence of risk factors (eg, diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, old age);
prevention of recurrent myocardial infarction;
unstable angina;
prevention of stroke (including patients with transient ischemic attack);
prevention of transient ischemic attacks;
prevention of thromboembolism after surgery and invasive procedures on vessels (eg, coronary artery bypass surgery, carotid endarterectomy, arterio-venous bypass, angioplasty of the carotid arteries);
prevention of deep vein thrombosis and pulmonary embolism and its branches (eg, prolonged immobilization as a result of a large surgical intervention).
Dosing regimen
Tablets, taken orally, before eating, drinking plenty of fluids. Prophylaxis for suspected acute myocardial infarction: 100-200 mg / day (the first pill must be chewed for faster absorption). Prevention first mooted acute myocardial infarction in the presence of risk factors: 100 mg / day.
Prevention of recurrent myocardial infarction, unstable angina, prevention of stroke and transient ischemic attacks, prevention of thromboembolic complications after surgery or invasive investigations: 100-300 mg / day.
Prevention of deep vein thrombosis and pulmonary embolism and its branches: 100-200 mg / day. The drug is designed for prolonged use. The duration of therapy is determined by your doctor.
Side effect
From the digestive system: nausea, heartburn, vomiting, pain in the abdomen, ulceration of the mucous membrane of the stomach and duodenum (including perforated), gastrointestinal bleeding, elevated liver enzymes.
With the respiratory system: bronchospasm.
From the hemopoietic system: increased bleeding, rarely - anemia.
CNS: dizziness, ringing in the ears. Allergic reactions: urticaria, angioedema, anaphylactic reaction.
Contraindications
erosive and ulcerative lesions of the gastrointestinal tract;
gastrointestinal bleeding;
hemorrhagic diathesis;
Bronchial asthma induced by intake of salicylates and NSAIDs, Fernand-Widal triad (a combination of asthma, recurrent polyposis of the nose and paranasal sinuses and the intolerance of acetylsalicylic acid);
combined use with methotrexate 15 mg per week or more;
I and III trimesters of pregnancy;
Lactation (breastfeeding);
age 18;
hypersensitivity to the drug;
hypersensitivity to other NSAIDs.
Caution should be used to treat gout, hyperuricemia, guidance on the history of gastrointestinal ulceration or gastrointestinal bleeding, kidney and liver failure, asthma, chronic respiratory disease, hay fever, nasal polyposis, allergic reactions to other drugs in the II trimester pregnancy, in combination with methotrexate at a dose of less than 15 mg per week. with vitamin K deficiency and glucose-6-phosphate dehydrogenase.
Pregnancy and lactation
The use of salicylates in high doses in the I trimester of pregnancy is associated with an increased frequency of fetal defects (split the sky, heart defects). In the II trimester salicylate may be given only on the basis of strict evaluation of the risks and benefits. In the III trimester of pregnancy salicylates in high doses (300 mg / day) cause inhibition of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and the appointment immediately before delivery may cause intracranial hemorrhage, especially in preterm infants. Appointment of salicylates in the III trimester of pregnancy is contraindicated. Salicylates and their metabolites in small amounts are excreted in breast milk.
Incidental taking of salicylates during lactation is not accompanied by the development of adverse reactions in children and does not require stopping breastfeeding. However, if necessary, prolonged use of a drug or appointing him to a high dose of breast-feeding should be stopped immediately.
Use in hepatic dysfunction
Caution should be used when specifying a history of liver failure. Use in renal impairment with caution should be used when specifying a history of renal failure.
Cautions
Aspirin can provoke bronchospasm and cause bronchial asthma and other hypersensitivity reactions. Risk factors are the presence of asthma history, hay fever, nasal polyposis, chronic respiratory system diseases, and allergic reactions to other drugs (eg, skin reactions, pruritus, urticaria).
Aspirin can cause bleeding of varying severity during and after surgery. The combination of aspirin with anticoagulants, thrombolytic and antiplatelet drugs is accompanied by an increased risk of bleeding. Aspirin in low doses can provoke the development of gout in susceptible individuals (who have a decreased excretion of uric acid).
The combination of acetylsalicylic acid with methotrexate is accompanied by a high incidence of side effects of hematopoiesis. High doses of aspirin have a hypoglycemic effect that must be borne in mind when assigning it to patients with diabetes receiving hypoglycemic medications.
When combined appointment of the SCS and salicylates should be borne in mind that during treatment the level of salicylate in the blood is reduced, and after withdrawal of GCS possible overdose of salicylates. Not recommended combination of acetylsalicylic acid and ibuprofen, as the latter affects the beneficial effect Aspikora on life expectancy. Excess doses of aspirin carries a risk of gastrointestinal bleeding.
Overdose is especially dangerous in elderly patients.
In combination with acetylsalicylic acid and alcohol increased the risk of gastrointestinal mucosal lesions and bleeding time prolongation.
Effects on ability to drive vehicles and management mechanisms
There were no effects of the drug's ability to drive vehicles and management mechanisms.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: a reduction in dose. Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory insufficiency, severe hypoglycemia.
Treatment: immediate hospitalization in a specialized department for emergency treatment - gastric lavage, determination of the acid-alkaline balance, alkaline and forced alkaline diuresis, hemodialysis, the introduction of solutions, activated charcoal, symptomatic therapy.
During alkaline diuresis is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be undertaken when the concentration of salicylate in plasma is more than 500 mg / L (3.6 mg / dL) in adults and 300 mg / L (2.2 mg / dL) in children.
No comments:
Post a Comment